Chemoresistance is a major problem in the chemotherapy of non‐small cell lung cancers
(NSCLCs). Several mechanisms are thought to be involved in drug resistance, including …

Chemotherapy is one of the important methods to treat cancer, and the emergence of
multidrug resistance (MDR) is one major cause for the failure of cancer chemotherapy …

The risk of acquisition of resistance to chemotherapy remains a major hurdle in the
management of various types of cancer patients. Several cellular and noncellular …

The management of cancer involves procedures, which include surgery, radiotherapy and
chemotherapy. Development of chemoresistance is a persistent problem during the …

Cancer treatment faces many hurdles and resistance is one among them. Anti-cancer
treatment strategies are evolving due to innate and acquired resistance capacity, governed …

Lung cancer is the leading cause of cancer‐associated death, and non‐small cell lung
cancer (NSCLC) accounts for 85% of all lung cancer cases. Many drugs have been used to …

Resistance to chemotherapy limits the effectiveness of anti‐cancer drug treatment. Tumours
may be intrinsically drug‐resistant or develop resistance to chemotherapy during treatment …

Immune checkpoint inhibitors (ICIs) have a huge impact on clinical treatment results in non-
small cell lung cancer (NSCLC). Blocking antibodies targeting programmed cell death …

All successful cancer therapies are limited by the development of drug resistance. The
increase in the understanding of the molecular and biochemical bases of drug efficacy has …

The development of oncoprotein-targeted anticancer drugs is an invaluable weapon in the
war against cancer. However, cancers do not give up without a fight. They may develop …